Elspeth McIntosh began her career in the pharmaceutical industry in 1993, initially working in clinical research, before moving into Pharmacovigilance. She has extensive experience of all aspects of pharmacovigilance and has been a small company QPPV since 1999, dealing with innovative, generic and biotech/biological products. Elspeth set up Castle Pharmacovigilance in 2009 and post Brexit she is a UK QPPV and UK National Contact Person for several small pharma companies and provides general PV support to a wide range of pharma companies.

Magnus Ysander has worked more than 20 years in the AstraZeneca pharmacovigilance organisation. Between 2015 and 2025 he was the EU and UK QPPV for the company and has also held several specialist, oversight and line managerial roles. Magnus now runs his own consultancy firm, providing both medical-scientific patient safety support and strategic guidance on comprehensive PV quality system management.